J10.0 B44.0 B44.1
Conditions
Interventions
Group 1: Study Classification
• Prospective Cohort: Participating ICU patients will be classified based on clinical criteria into two groups:
- IAPA (Influenza-Associated Pulmonary Aspergillosis).
- N
Sponsors
Medizinische Universität Graz
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Confirmed influenza infection by laboratory testing (e.g., PCR, antigen testing) For the retrospective cohort only: Availability of >0.2mL remaining BAL sample for testing the genetic phenotype.
Exclusion criteria
Exclusion criteria: Patients under the age of 18 years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To validate the clinical association between the genetic variations in the LGALS3 locus and the incidence of IAPA in an independent cohort of critically ill patients with severe influenza. | — |
Secondary
| Measure | Time frame |
|---|---|
| Preclinical Validation: • To validate and expand the pre-clinical evidence supporting a causal relationship between LGALS3 variation and antifungal effector functions of immune cells, such as phagocytosis, reactive oxygen species production, and fungal killing in response to Aspergillus infection under influenza-induced stress conditions. • To investigate the impact of LGALS3 variation on the cellular localization, expression, and stability of galectin-3, as well as its downstream effects on immune cell metabolism. Multi-Omics Analysis: • To integrate genetic, transcriptomic, proteomic, metabolomic, and microbial data from critically ill flu patients to identify of molecular pathways and mechanisms altered by LGALS3 variations. • To stratify patients based on genotype-specific molecular profiles and develop a comprehensive LGALS3-based risk score model to predict IAPA risk. Interventional Trial Preparation: • To design a clinical trial protocol for targeted antifungal prophylaxis using validated LGALS3 SNP(s) as companion biomarkers for patient stratification. • To assess the health-economic impact of genetic stratification by comparing outcomes of LGALS3-targeted prophylaxis, universal prophylaxis, and standard care. • To conduct a social science analysis involving ICU patients, families, and healthcare providers to address ethical considerations, feasibility, and societal acceptance of genetic testing in ICU settings. | — |
Countries
Austria, Belgium, France, Netherlands, Portugal
Contacts
Public ContactMartin Hönigl
Klinische Abteilung für Infektiologie, Medizinische Universität Graz
Outcome results
None listed